New drug combo trial offers hope for transplant patients with severe immune reaction
NCT ID NCT06233110
Summary
This early-stage study is testing whether adding fostamatinib to the standard drug ruxolitinib is safe and effective for chronic graft-versus-host disease that doesn't respond well to steroid treatment. The trial will enroll about 30 adults who have had a stem cell transplant and developed this immune complication. Researchers aim to find the best dose of the drug combination that balances safety with biological activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Conditions
Explore the condition pages connected to this study.